期刊文献+

炔雌醇环丙孕酮联合二甲双胍治疗肥胖型多囊卵巢综合征的疗效分析 被引量:7

Efficacy of ethinylestradiol and cyproterone combined with metqormin in the treatment of patients with obesity and polycystic ovary syndrome
下载PDF
导出
摘要 目的分析炔雌醇环丙孕酮与二甲双胍联合治疗肥胖型多囊卵巢综合征患者的临床效果。方法选取中山市博爱医院妇科2013年3月至2014年3月收治的80例肥胖型多囊卵巢综合征患者,按随机抽样法分为对照组和观察组,各40例。对照组单纯给予炔雌醇环丙孕酮片进行治疗,观察组采用炔雌醇环丙孕酮片联合二甲双胍治疗。结果治疗前两组BIM、FIN、IR、T、FSH、LH、E2均无差异(P>0.05);治疗后观察组除BIM外,FIN、IR、T、FSH、LH、E2均低于对照组(P<0.05)。结论炔雌醇环丙孕酮片联合二甲双胍对肥胖型多囊卵巢综合征效果显著,可有效调节卵巢激素的分泌,值得临床应用及推广。 Objective To study the efficacy of ethinylestradiol and cyproterone combined with metqormin in the treatment of pa-tients with obesity and polycystic ovary syndrome.Methods 80 patients with obesity and polycystic ovary syndrome treated from March of 2013 to March of 2014 in Zhongshan Boai Hospital were selected and randomly divided into two groups,40 cases in each group.The control group was treated with ethinylestradiol and cyproterone and observation group was treated with ethinylestradiol and cyproterone combined with metqormin.Results Before treatment,BIM,FIN,IR,T,FSH,LH and E2 of two groups were not different (P 〉0.05).After treatment,FIN,IR,T,FSH,LH and E2 of observation group were lower than those of control group (P 〈0.05).Con-clusion For patients with obesity and polycystic ovary syndrome,ethinylestradiol and cyproterone combined with metqormin has an ob-vious efficacy and could efficiently adjust the secretion of ovarian hormone.It is worthy of clinical application and promotion.
出处 《河南医学研究》 CAS 2015年第5期21-22,共2页 Henan Medical Research
关键词 肥胖 多囊卵巢综合征 二甲双胍 炔雌醇环丙孕酮 obesity polycystic ovary syndrome metqormin ethinylestradiol and cyproterone
  • 相关文献

参考文献5

二级参考文献32

  • 1李梅,李志凌,李红发.多囊卵巢综合征卵泡闭锁调节机制的研究进展[J].生殖医学杂志,2004,13(6):377-380. 被引量:14
  • 2冯淑英.PCOS胰岛素抵抗发生机制与无排卵[J].实用妇产科杂志,2005,21(9):517-519. 被引量:24
  • 3梁竹巍,王蕊.二甲双胍治疗多囊卵巢综合征新进展[J].国外医学(妇产科学分册),2006,33(6):414-417. 被引量:19
  • 4乐杰.妇产科学[M].7版.北京:人民卫生出版社,2007:374.
  • 5Manzanares MA, Gomez - Palomares JL, Riceiareni E, et al. Triggering ovulation with gonadotropin - releasing hormone agonist in in vitro fertilization patients with polycystic ovaries does not cause ovarian hyperstimulation syndrome despite very high estradiol levels. Fertility and Sterility,2010,93(4) :1215 - 1219.
  • 6Kahnberg A, Enskog A, Brannstrom M, et al. Prediction of ovarian hyperstimulation syndrome in women undergoing in vitro fertilization. Acta Obstetrieia et Gynecologica Scandinavica ,2009,88 ( 12 ) : 1373 - 1381.
  • 7Smith LP, Hacker MR, Alper MM. Patients with severe ovarian hyperstimulation syndrome can be managed safely with aggressive.outpatient transvaginal paracentesis. Fertility and Sterility, 2009,2 ( 6 ) : 1953 - 1959.
  • 8BeUver J, Pellicer A. Ovarian stimulation for ovulation induction and in vitro fertilization in patients with systemic lupus erythematosus and antiphospholipid syndrome. Fertility and Sterility, 2009,92 (6) :1803 - 1810.
  • 9Vloeberghs V, Peeraer K, Pexsters A. Ovarian hyperstimulation syndrome and complications of ART. Best Practice and Research : Clinical Obstetrics and Gynaecology ,2009,23 ( 5 ) :691 - 709.
  • 10Prakash A, Karasu T, Mathur R. Ovarian hyperstimulation syndrome: pathophysiology, prevention and management. Obstetrics, Gynaecology and Reproductive Medicine, 2009, 19 (9) : 247 - 252.

共引文献134

同被引文献31

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部